FILTER

Refine your search with the following facets to narrow down your results.

6 Current news of Viralytics

Viralytics Reports Positive Final Results from CAVATAKTM Phase 2 Melanoma Trial

03-Jun-2015 - Viralytics Limited provided positive final data from the Phase 2 CALM clinical trial of Viralytics’ lead drug candidate, CAVATAKTM, at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015. CAVATAK is an investigational cancer immunotherapy based on a proprietary bioselected common ...

cancer CAVATAK immunotherapies +1

CAVATAK Phase II Melanoma Study achieves interim efficacy subgoal

20-Dec-2012 - Viralytics Limited (VLA) in its US-based Phase II melanoma trial of its virotherapy candidate CAVATAKTM has achieved an interim efficacy subgoal of three Objective Responses (OR). This follows a recent review by the independent Data Monitoring Committee (DMC) of the trial. In the Phase II trial ...

CAVATAK melanoma phase II studies +1

Starpharma VP Dr Malcolm McColl appointed CEO of Viralytics

16-Nov-2012 - Starpharma Vice President Dr Malcolm McColl has been appointed Chief Executive Officer of Viralytics Limited.From 2010 Dr McColl was Vice-President of Business Development at Starpharma where he was responsible for completion of partnering transactions with global and regional companies. He ...

appointments

Viralytics strengthens US patent portfolio

01-Apr-2009 - Viralytics Limited has been granted a key patent by US authorities covering the use of Echoviruses (including EVATAKTM) for the treatment of all cancers expressing the integrin a2b1 molecule. EVATAK™ is the trade name for Viralytics’ proprietary formulation of the Echovirus Type 1 (EV1). EV1 ...

gastric cancer

Viralytics broadens IP portfolio

07-Nov-2008 - Viralytics Limited has received a Notice of Allowance from the United States Patent Office for its patent application covering the use of Echoviruses (including EVATAKTM) for the treatment of all cancers bearing expression of the integrin a2b1. EVATAKTM is the trade name for Viralytics’ ...

Expression oncolytic viruses prostate cancer

Viralytics secures key EU patent

29-Oct-2008 - Viralytics Limited announced that the company has been granted a European patent covering the company’s core technology. The Company had announced in May 2008 that a “Notice of Allowance” had been received and that subject to the completion of a number of administrative matters a patent was ...

patents viruses